Emergent BioSolutions Inc.

NYSE:EBS

Biotechnology

Healthcare
$5.50 -2.58%

-$0.21 today

Market cap
$282.78M
Beta
2.33
P/E (TTM)
-47.9
EPS (TTM)
-$0.17
52W Low $5.62High $14.06

Volume 0.82M

Average 0.78M

EBS Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Emergent BioSolutions Inc.NYSE: EBS

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $1.9M rose 26.7% year over year, ahead of the +22.1% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 64.2% from the prior quarter. Over 3 fiscal years it compounded at -28.9% a year.

Context

  • Stock-based compensation amounted to 2.2% of revenue in FY2025, up 0.5 pp from a year earlier.
  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +26.7% holds above the trailing-twelve-month pace of +22.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.9M-64.2% QoQ
Last fiscal yearDec 2025
$16.2M-10.0% YoY
LTMMar 2026
$16.6M+22.1% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+26.7%——
1 year-10.0%——
3-year CAGR-28.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
16.2M USD
Year-over-year change
-10.0%
4-year CAGR
-21.4%

Stock-Based Compensation vs competitors

How EBS compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +22.1% is the 2nd highest of 11, against a peer median of -4.1%.
  • Stock-based compensation amounts to 2.5% of revenue for EBS, versus a peer median of 3.8%.
EBS Competitors
Stock-Based Compensation for EBS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRTAProthena Corporation plcLTM Mar 2026$33.61M USD-24.5%+6.3%58.0%
EBSEmergent BioSolutions Inc.LTM Mar 2026$16.6M USD+22.1%-28.9%2.5%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$13.57M USD+17.6%+26.6%2.6%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$13.21M USD-40.1%——
SNDLSNDL Inc.LTM Mar 2026CA$13.13M CAD-20.8%+12.9%1.4%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$12.84M USD+21.4%+0.9%4.3%
CMPSCOMPASS Pathways plcLTM Mar 2026$12.55M USD-31.5%+1.2%—
ESPREsperion Therapeutics, Inc.LTM Mar 2026$9.91M USD-11.7%-13.4%2.4%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$8.36M USD+17.6%+20.3%16.6%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$6.73M USD+88.8%+25.6%—
SIGASIGA Technologies, Inc.LTM Mar 2026$3.53M USD+3.6%+27.4%3.8%
Peer median (excluding EBS) —-4.1%+12.9%3.8%

Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income230.9M(211.6M)(760.5M)(190.6M)52.6M
Depreciation & Amortization123.8M143.3M125.1M108.8M95.8M
Deferred Income Tax46.9M(28.6M)(8.9M)(5.5M)(4M)
Stock-Based Compensation42.4M45.1M23.1M18M16.2M
Change in Working Capital(156.4M)(2.1M)(70.3M)88.7M(22.4M)
Accounts Receivables(48.2M)118.1M(21.6M)(24.4M)25.5M
Inventory(44M)(57.1M)600K(24.5M)(30.3M)
Accounts Payables(2.5M)(14M)10.6M(33M)(8.4M)
Other Working Capital(61.7M)(49.1M)(59.9M)170.6M(9.2M)
Other Non-Cash Items33.5M19.8M485.2M39.3M32.4M
Operating Cash Flow321.1M(34.1M)(206.3M)58.7M170.6M
Capital Expenditures(225M)(115.8M)(51.6M)(22.9M)(13.8M)
Acquisitions (Net)00270.2M00
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0(265.5M)(6.3M)148.1M83.2M
Investing Cash Flow(225M)(381.3M)212.3M125.2M69.4M
Debt Repayment(35.9M)564.2M(543.4M)(198.4M)(112.5M)
Common Stock Issued008.4M9.3M2.2M
Common Stock Repurchased(106M)(82.1M)00(24.9M)
Dividends Paid00000
Other Financing Activities900K(900K)(700K)(900K)(1.4M)
Financing Cash Flow(141M)481.2M(535.7M)(190M)(136.6M)
Effect of Forex Changes(300K)500K(1.2M)0100K
Net Change in Cash(45.2M)66.3M(530.9M)(6.1M)103.5M
Free Cash Flow96.1M(149.9M)(257.9M)35.8M156.8M

Emergent BioSolutions Inc.

NYSE:EBS

Intrinsic Alpha fair value

Locked

Current Price

$5.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.